Continuous glucose monitoring holds significant promise for patients with type 2 diabetes who are not treated with insulin.

From manufacturer rebates to risk corridors, Milliman pharmacy experts discuss strategies for paying for high-cost drugs.

In this paper, after covering background on SCD, the new gene therapies, and the CMMI model, we leverage Milliman’s data assets to provide a high-level overview of the landscape of individuals with SCD and the providers who treat them.

Amid the development of new cell and gene therapies, we present some strategies that states have used to control costs and risk among their MCOs.

We explore the recent growth in utilization and spending in Medicaid for glucagon-like peptide-1 agonists, used for type 2 diabetes and chronic weight management.

As a new federal law, effective in 2024, removes a cap on manufacturers' drug rebate amounts, we explore the implications for state Medicaid programs.